In human immunodeficiency virus (HIV) disease, symptoms of underlying illness may promote weight loss through decreased caloric intake, increased metabolic needs, or nutrient malabsorption. We evaluated disease symptoms as predictors of acute weight loss (i.e., loss of у5% of weight). HIV-infected men and women ( ) were telephoned every 5 weeks to obtain information about weight and recent symptoms. Weight n p 415 change between each pair of consecutive calls (telephone intervals, 2814) was calculated. Acute weight loss occurred across 4.5% of intervals and among 24% of individuals. Patients reported у1 symptom before 58% of telephone intervals. The most common symptoms or symptom complexes before intervals were diarrhea (21% of patients), anorexia (17%), upper respiratory symptoms (16%), skin symptoms (12%), and abdominal pain (12%). Trouble swallowing (6%) and oral symptoms (7%) were less common. Risk of acute weight loss was significantly increased when oral symptoms or trouble swallowing were present, and it was decreased when highly active antiretroviral therapy (HAART) was used or when diarrhea was not present. Even when HAART is being administered, clinicians should remain vigilant regarding weight loss, oral symptoms, and trouble swallowing.
cation of symptoms that predict weight loss could lead to earlier preventive interventions.
Weight loss may be caused by decreased caloric intake, malabsorption, or increased energy expenditure. Acute episodes of weight loss in the pre-HAART era were associated with opportunistic infections (OIs), including Pneumocystis carinii pneumonia and tuberculosis. Although it is difficult to determine the cause of weight loss, symptoms might be markers of underlying factors promoting weight loss, such as shortness of breath and fatigue. Anorexia, presence of mouth sores, vomiting, nausea, and trouble swallowing may limit caloric intake. Bloating may be related to clinical or subclinical nutrient malabsorption suggesting underlying nutritional compromise. Fever may result in increased resting energy expenditure. Symptoms are often not specific to individual infections. Moreover, in the HAART era, diarrhea, nausea, and anorexia may also be related to medications and could reduce intake or absorption of nutrients or antiretrovirals. It is difficult to distinguish the effects of medications from those of disease.
Two longitudinal studies from the pre-HAART era found that symptoms predicted weight loss. In homosexual/bisexual men, fatigue that occurred 1-1.5 years before onset of weight loss was a risk factor for loss of у10% of weight, whereas oral thrush predated this weight loss at a shorter interval (6 months before onset) [11] . In injection drug users, diarrhea predicted у10% loss of body weight from baseline [12] . Neither study calculated weight loss over short intervals or determined symptom severity.
To more accurately diagnose impending acute weight loss, we examined various symptoms and symptom severity at 5-week intervals in a diverse cohort of persons with HIV infection in both the pre-HAART and HAART eras. We addressed 2 questions: (1) do symptoms trigger an episode of acute weight loss, and (2) does HAART use decrease the impact of symptoms on risk of acute weight loss?
METHODS

Participants
Participants were enrolled in Nutrition for Healthy Living, a prospective longitudinal study of nutrition and HIV infection. We continued to recruit participants over time, so the lengths of follow-up vary. This analysis includes information obtained from April 1995 through June 1999. The methodology is reported elsewhere [1, [13] [14] [15] [16] . Informed consent was obtained from each participant, as approved by the institutional review boards at Tufts School of Medicine (Boston) and Miriam Hospital (Providence, RI). At semiannual clinic visits, we obtained demographic data, medical history (including antiretroviral use, complete blood cell count, albumin level, CD4 + lymphocyte count, HIV load, and caloric intake), data on dieting and whether the patient experienced depression, and behavioral history since the last clinic examination. Between visits, participants were telephoned approximately every 5 weeks to obtain current data on weight and symptoms since the previous contact by telephone or visit.
Data Collection
Weight reported by telephone. Everyone was given a scale at enrollment. By telephone, participants reported their current weight (within the past 7 days). The correlation between weight reported by telephone and weight recorded at the previous visit within 30 days was 0.98 ( ). P р .0001 Symptoms reported by telephone. At every call, participants reported whether the following symptoms had occurred since the previous contact: abdominal pain, cough, diarrhea, fever (temperature, 138.06ЊC [1100.5ЊF]), loss of appetite, mouth sores, shortness of breath, skin rashes, trouble swallowing, vomiting, and other symptoms (excluding headaches). For each symptom, start and stop dates, diagnosis, and treatment were noted. Symptom severity was determined by answering the question, "How does it interfere with your normal activities?" ("not at all," "very little," "moderately," "quite a bit," or "extremely").
Determination of symptom complexes from telephone data. Two physicians evaluated all data obtained via the telephone. They categorized the constellation of symptoms and diagnoses occurring together into symptom complexes (genital tract, hepatobiliary, upper respiratory tract, lower respiratory tract, oral, nervous system, psychological, skin, systemic, urinary tract, and other). The predominant symptoms determined the symptom complex, and severity was defined by the symptom with the worst severity in the symptom complex. Gastrointestinal (GI) symptoms (anorexia, trouble swallowing, vomiting, abdominal pain, and diarrhea) were not aggregated into a symptom complex but were evaluated individually. Oral symptom complex and trouble swallowing were combined for the final multivariate analysis to describe symptoms that interfere with food intake. Symptom complexes and GI symptoms that resolved and recurred again were recorded as separate incidents.
Demographic and clinical characteristics recorded at semiannual visits. HAART was defined as therapy with у2 nucleoside reverse-transcriptase inhibitors with either a protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor, or as dual-protease inhibitor therapy. HIV load was measured using the Roche Amplicore Monitor reverse-transcriptase PCR assay (Roche Molecular Systems), which has a lower detection limit of 400 copies/mL. Levels у5 log 10 were categorized as a "high HIV load." From 3-day food intake records, caloric intake per kilogram of body weight was calculated using the Nutrition Data System for Research [17] . Participants were also asked whether they tried to lose weight (i.e., by dieting). Occurrence of depression was determined using an 8-item screening instrument with yes/no responses [18] . Poverty was defined as living below the 1998 federal poverty level [19] . AIDS-defining OIs are those in the 1992 Centers for Disease Control and Prevention classification [20] , excluding esophageal candidiasis, bronchopulmonary candidiasis, and herpes, because it was difficult to distinguish these from oral candidiasis or localized herpes by self-report. call, the telephone interval was excluded. The median number of days between calls included was 36 (interquartile range, 30-51). Each participant with data from у1 telephone interval (i.e., 2 calls) was included.
Acute weight change for each telephone interval was calculated as the weight at the end of the interval minus the weight at the start. Negative values indicate weight loss.
Recent symptom complexes and GI symptoms that began 1-60 days before a telephone interval started were assigned to that interval. If a symptom complex or GI symptom occurred within 1-60 days before other telephone intervals, it was assigned to those intervals too. Recent demographic and clinical variables assigned to each telephone interval were those from the closest previous semiannual visit.
Statistical Analysis
The dependent variable, acute weight loss, was у5% loss in weight during a telephone interval. At no time does acute weight loss mean a !5% loss in weight or a weight gain. The independent variable was presence or absence of each symptom complex or GI symptom р60 days before the start of a telephone interval. Potential confounders were demographic and clinical variables from the visit preceding the telephone interval. In the final model, the demographic and clinical variables were also evaluated as independent predictors. We included all records with complete data on all potential confounders, except HIV load and dieting, for which missing indicator variables were used.
We conducted analyses of the relationship between symptom complexes/GI symptoms and acute weight loss in 3 stages. First, in a separate model for each symptom complex/GI symptom, we obtained a relative risk (RR) of acute weight loss, adjusted for confounding [21] , from generalized estimating equations (GEE) with a log link (using the PROC GENMOD procedure on SAS software, version 8.0 [SAS Institute]) [22] . We used GEE because data from multiple telephone intervals contributed by a participant are not independent [22] . Inference on RRs was performed using robust SEs of estimated effects. We present 95% CIs and Wald P values.
Next, each of the adjusted models described above was tested for effect modification by HAART. We also examined whether severity of each symptom complex/GI symptom was predictive of acute weight loss. Finally, using backward elimination, we determined the best predictors of acute weight loss from symptom complexes/GI symptoms and demographic and clinical characteristics that were significant ( ) on bivariate analy-P ! .2 sis. Those with a P value of р.1 were kept in the final model to include trends, because the sample size was small for some symptom complexes/GI symptoms.
We also evaluated the population-attributable risk of symptoms on acute weight loss, as described by Miettinen [23] . In addition, we used GEEs with the identity link to determine the robust variance for the average change in weight across all telephone intervals.
RESULTS
Demographic and clinical characteristics. There were 415 participants included in this study. The mean age of the cohort was 40 years (table 1). The majority of the participants were 3 , and an HIV load of 15 log 10 copies/mL was observed in 18%. Approximately one-third of the participants were depressed, 8% were obese (body mass index, 130), and 22% had tried to lose weight. Men had completed significantly more telephone calls than women, and persons living in poverty and current injection drug users completed fewer calls (data not shown).
Acute weight loss. Acute weight loss was reported for 127 telephone intervals among 415 participants. One hundred participants (24%) had у1 episode of acute weight loss, and 36 (9%) experienced multiple episodes. On average, the amount of weight loss (‫ע‬SE) in percentage of body weight across all telephone intervals was . The median change 0.001% ‫ע‬ 0.0004% in weight among all participants was 0%. Thus, there was an equal amount of weight gained and weight lost. Of the 2814 telephone intervals, acute weight loss of у5% occurred during 4.5% of intervals, and acute weight loss of у10% occurred during 1.0% of intervals.
Symptom prevalence. The median number of telephone intervals with data per participant was 5 (interquartile range, 2-9; range, 1-27). A median of 1.4 symptom complexes/GI symptoms occurred per person-telephone interval. The frequency of symptom complexes/GI symptoms, according to weight loss category, is shown in table 2. When weight loss and 
4) .03
Nervous system symptom complex 2.4 (0.9-6.6) .09
HIV transmission risk factor of male-male sexual contact 0.7 (0.5-0.96) .03
Albumin level (g/dL) 0.7 (0.5-1.00) .05
HAART and diarrhea interaction … .04
NOTE. See figure 1 for incidence of weight loss for diarrhea and HAART interaction. RR, relative risk.
a The model was adjusted for duration of the telephone intervals, diarrhea, receipt of HAART, and the interaction between HAART and diarrhea ( ). P p .04 non-weight loss intervals were added together, у1 symptom complex/GI symptom was found to have occurred before 58.2% of the intervals. The most prevalent symptom complexes/GI symptoms reported before all telephone intervals were diarrhea (21.5%), anorexia (17.5%), upper respiratory tract symptom complex (15.8%), skin-related symptom complex (12.2%), and abdominal pain (11.7%). Lower respiratory tract symptom complex (8.8%), vomiting (8.8%), oral symptom complex (6.7%), systemic symptom complex (6.1%), and trouble swallowing (5.7%) were less common. Other symptom complexes were reported to have occurred before !5% of all telephone intervals.
Risk of acute weight loss, by symptom complex/GI symptom. In analyses of individual symptom complexes and GI symptoms, 4 were found to have predicted acute weight loss with a significance of (table 2): trouble swallowing (RR, P р .1 1.7; 95% CI, 0.96-2.8), oral symptom complex (RR, 1.5; 95% CI, 1.1-2.7), systemic symptom complex (RR, 1.6; 95% CI, 0.9-2.8), and nervous system symptom complex (RR, 2.8; 95% CI, 0.9-8.5). Fever, shortness of breath, and cough did not predict acute weight loss (data not shown). We only found a significant interaction for diarrhea; this was between diarrhea and HAART (
). This means that the relationship be-P p .04 tween diarrhea and weight loss is not the same at different levels of HAART use. Thus, among HAART recipients, the RR of acute weight loss for persons with diarrhea, compared with persons without diarrhea, was 1.9 (95% CI, 1.05-3.3; P p ). In addition, among persons who did not use HAART, the .03 RR for weight loss for persons with diarrhea, compared with persons who did not have diarrhea, was 0.77 (95% CI, 0.4-1.4;
). Severity of a symptom complex or GI symptom did P p .38 not increase the risk of acute weight loss in any case.
Among 13 participants with oral symptom complex and acute weight loss, mouth sores were the most common symptom (13 participants), followed by loss of appetite (3 participants) and trouble swallowing (1 participant). There was little overlap between oral symptom complex and trouble swallowing among those with acute weight loss. Among 17 HAART recipients with diarrhea who lost weight, other symptoms included abdominal pain (6 participants), loss of appetite (4 participants), vomiting (3 participants), trouble swallowing (1 participant), and mouth sores (1 participant). Among 3 participants who lost weight and had a nervous system complex, the most common symptoms were "other" (seizures, neuropathy, vertigo in 1 participant each) and fever (2 participants). Among 12 participants with systemic symptom complex and acute weight loss, the most common symptoms were fever (10 participants), shortness of breath (6 participants), cough (5 participants), anorexia (5 participants), and mouth sores (4 participants).
Independent predictors of acute weight loss. In the final model, trouble swallowing or oral symptom complex (table 3) was a significant independent predictor of increased risk of acute weight loss (RR, 1.6; 95% CI, 1.04-2.4). Men who have sex with men were less likely to lose weight (RR, 0.7; 95% CI, 0.5-0.96), and, with each 1 g/dL-increase in the albumin level, there was a decrease in the RR of acute weight loss of 0.7 (95% CI, 0.5-1.0). The relationship between HAART use and weight loss differed according to level of diarrhea, as shown by the significant interaction term between diarrhea and HAART ( ). (See figure 1 for the incidence rates of acute weight P p .04 loss by diarrhea status and HAART use.) Among participants without diarrhea, HAART use versus no HAART use was protective of acute weight loss (RR, 0.5; 95% CI, 0.3-0.7; P p ). In contrast, in participants with diarrhea, there was no .0005 relationship between HAART use and acute weight loss (RR, 1.1; 95% CI, 0.5-2.1;
). Because interaction terms are P p .84 reciprocal, the interaction term can also be interpreted as the relationship between diarrhea and weight loss at different levels of HAART use. Thus, among HAART recipients, those who had diarrhea showed a trend toward more acute weight loss, compared with those who did not have diarrhea (RR, 1.7; 95% CI, 0.96-3.0;
). Among nonrecipients of HAART, di-P p .07 arrhea was not associated with acute weight loss, compared with absence of diarrhea (RR, 0.7; 95% CI, 0.4-1.3;
). P p .33 In addition, participants with nervous system complex had no significant increased independent risk of acute weight loss ( ). Fifteen percent of the risk of acute weight loss was P p .09 attributable to trouble swallowing, oral symptom complex, nervous system complex, or diarrhea among HAART recipients.
DISCUSSION
To our knowledge, this is the first study that assesses the relationship between symptoms and acute weight loss in the HAART era. We report several new findings. First, 24% of participants had у1 episode of acute weight loss. The incidence of acute weight loss per telephone interval was 4.5%, and, during 1% of telephone intervals, there was у10% weight loss. . The relative risks (RRs) can be computed from this P p .04 figure by dividing the incidence rates. For example, among those without diarrhea, the RR of weight loss for receipt of HAART, compared with no receipt of HAART (non-HAART), is 0.5 (1.8/3.7). Among those with diarrhea, the RR of weight loss for HAART vs. non-HAART is 1.07 (3/2.8).
Second, acute weight loss was associated with oral symptom complexes and trouble swallowing, but not with anorexia. Third, we discovered an interaction between HAART use and diarrhea, probably representing clinically important effect modification. Among participants without diarrhea, HAART use was protective against acute weight loss. In contrast, among those with diarrhea, HAART use was not associated with weight loss. Finally, 15% of the increased risk of acute weight loss was explained by the occurrence of oral symptom complex, trouble swallowing, nervous system complex, or diarrhea among HAART recipients. Even in the HAART era, weight loss is not uncommon, as we showed previously using a different analytic approach [1] .
As others have found [24, 25] , disease symptoms are common among HIV-positive patients. We found that у1 symptom was reported before nearly 60% of telephone intervals. However, as in the general US population [26, 27] , our participants reported numerous symptoms that were likely unrelated to HIV infection, including colds and other respiratory diseases, thus complicating clinical evaluation. Occurrence of more symptoms [24] and of specific symptoms are clearly associated with worse health-related quality of life [28] . However, few investigators have examined the association between symptoms and acute weight loss.
We observed that acute weight loss might be explained partially by symptoms that prevent adequate caloric intake. Patientreported symptoms have been shown elsewhere to be important independent predictors of weight loss [11, 12] . Symptoms may impose barriers to food intake [29] , be indicators of nutrient malabsorption [30] , or be indicators of illnesses that change metabolic needs and decrease physical activity [29, 31] . Macallan and colleagues [29, 31] argue that the primary factor driving acute weight loss is reduced intake or anorexia mediated by HIV and secondary infections. In our study, symptoms that might interfere with food intake (oral symptom complex and trouble swallowing) were predictive of acute weight loss, but anorexia was not. Oral symptoms involved mouth sores, mostly due to thrush, which may make eating painful and/or be a marker for increased HIV disease activity. Graham et al. [11] also found that oral thrush was a predictor of weight loss of у10% over a 6-month period.
The relationship between HAART use and weight loss is poorly understood. Two small studies [15, 32] have suggested that HAART use is associated with weight gain, and 1 larger study [1] found no change in weight among HAART recipients. Our detailed analysis of individual symptoms may shed some light on this important question. We used an interaction term (HAART*diarrhea) in the model to explain how the relationship between HAART (predictor) and weight loss (outcome) differed in different categories of diarrhea. We found that, among patients without diarrhea, HAART recipients had a lower risk of weight loss than did persons who did not receive HAART. However, among participants with diarrhea, HAART recipients had the same risk of weight loss as those who did not receive HAART. Because interaction terms are reciprocal, we were also able to examine the relationship between diarrhea (predictor) and weight loss (outcome) in different categories of HAART use. Among HAART recipients, there was only a trend for those who had diarrhea to have a greater risk of weight loss, compared with those who did not have diarrhea. There was no significant relationship between diarrhea and weight loss among participants who did not receive HAART. Previously, in our cohort, Knox et al. [16] showed that 47.6% of participants had intestinal dysfunction, as determined by low serum d-xylose levels, and 40% had diarrhea in the month before a study visit. There are several possible explanations for effect modification between diarrhea and receipt of HAART on acute weight loss. First, in the absence of diarrhea, HAART use increases overall health and stimulates appetite and, thus, prevents acute weight loss. Second, HAART, which has known gastrointestinal toxicities, may worsen existing diarrhea and, with it, nutrient malabsorption, resulting in acute weight loss. Third, patients with diarrhea do not absorb antiretrovirals well and, consequently, have a reduced antiretroviral-associated effect on weight. We cannot distinguish between these possible explanations. For clinicians, the important message is that the protective effects of HAART on acute weight loss may be attenuated in patients with diarrhea.
Our study provided a unique opportunity to study acute weight loss, because we made frequent measurements of weight and symptoms, before and during the HAART era, among men and women at different stages of HIV infection. Macallan et al. [29] studied acute weight loss during HIV disease entirely among patients with AIDS before the HAART era. Their time interval was similar to ours. However, their results differ in that 25% of our participants experienced acute weight loss, compared with 54% of participants in their study. In addition, fewer of our participants had multiple episodes of weight loss (9% vs. 30%). The difference between the 2 studies may be related to the 33% prevalence of AIDS-defining conditions (other than CD4 + lymphocyte count of !200 cells/mm 3 ) in our study, compared with the 100% prevalence in the study by Macallan et al. [29] . In addition, the overall protective effects of HAART in our cohort may have reduced the number of OIs or other unexplained factors that contribute to HIV progression and acute weight loss. This is supported by the lower risk of acute weight loss overall among HAART recipients without diarrhea in our study.
One might guess that systemic or lower respiratory tract illnesses might affect acute weight loss through an increase in resting energy expenditure that is reflected in fever. However, Macallan and colleagues [29, 31] suggest that anorexia experienced during an OI, a non-HIV-related lower respiratory tract infection, or a systemic illness may be a more prominent contributor to acute weight loss than increased resting expenditure or total energy expenditure. This may be true for neurologic symptoms as well. In fact, in our study, GI symptoms sometimes accompanied lower respiratory or systemic symptom complexes. However, anorexia alone did not predict acute weight loss in our cohort. Most cases of anorexia were probably mild and due to minor respiratory illnesses, because there were few new OIs in our cohort because of HAART.
Some limitations to the study may have weakened our findings. Participants may not have easily recalled all recent symptoms and start dates, or they may not have responded to telephone calls if they were severely ill, depressed, or impoverished. However, depression and poverty were not associated with the outcome we were studying, acute weight loss. We had information about medications at the previous visit, but not at the exact time that symptoms occurred. We found similar results, however, when we omitted data from intervals with clinical information that occurred 19 months from the beginning of the interval. Finally, we cannot be sure that interventions aimed at eliminating or reducing the predictors we used will decrease acute weight loss, because this was not an intervention trial.
Even in the HAART era, physicians need to remain vigilant about their patients' weight and to carefully investigate all episodes of weight loss. Oral symptoms and trouble swallowing merit special attention in the clinical setting because of their association with acute weight loss.
